A randomized double-blind multi-dose placebo-controlled study to evaluate the efficacy safety and tolerability of GSK2330672 administration for the treatment of pruritus in patients with primary biliary cholangitis (GLIMMER: GSK triaL of IBAT inhibition with Multi-Dose Measurement for Evaluation of Response)
-
- STATUS
- Not Recruiting
Updated on 19 February 2024
Summary
The purpose of this study is to evaluate the efficacy, safety, and tolerability if a range of doses of GSK2330672 for the treatment of adults with moderate to severe pruritus associated with primary biliary cholangitis (PBC).
Description
The purpose of this study is to evaluate the efficacy, safety, and tolerability if a range of doses of GSK2330672 for the treatment of adults with moderate to severe pruritus associated with primary biliary cholangitis (PBC).
Details
| Condition | pruritus |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX8007 |
| Last Modified on | 19 February 2024 |
How understandable was the trial content above?
Hard to understand
Easy to understand
Similar trials to consider
Loading...
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.